Novartis to Supply Leqvio to the UK’s National Health Service

Novartis has reached an agreement with the UK’s National Health Service to offer its potential blockbuster cholesterol-lowering drug Leqvio (inclisiran) for an undisclosed price.

The deal, which followed a cost-benefit review by the UK’s National Institute for Health and Care Excellence, will enable approximately 300,000 patients at high risk of a second cardiovascular event to be treated over three years.

Leqvio (inclisiran) is given as a 6-month maintenance dose for individuals with elevated low-density lipoprotein cholesterol who do not show an adequate response to statins.